Handa Pharmaceuticals Statistics

Total Valuation

Handa Pharmaceuticals has a market cap or net worth of TWD 8.15 billion. The enterprise value is 5.66 billion.

Market Cap	8.15B
Enterprise Value	5.66B

Important Dates

The next estimated earnings date is Thursday, December 26, 2024.

Earnings Date	Dec 26, 2024
Ex-Dividend Date	n/a

Share Statistics

Handa Pharmaceuticals has 141.20 million shares outstanding. The number of shares has increased by 7.81% in one year.

Current Share Class	n/a
Shares Outstanding	141.20M
Shares Change (YoY)	+7.81%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	3.83%
Owned by Institutions (%)	1.47%
Float	85.51M

Valuation Ratios

The trailing PE ratio is 17.80 and the forward PE ratio is 3.61.

PE Ratio	17.80
Forward PE	3.61
PS Ratio	8.27
PB Ratio	2.81
P/TBV Ratio	n/a
P/FCF Ratio	10.94
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 7.59.

EV / Earnings	12.50
EV / Sales	5.81
EV / EBITDA	10.46
EV / EBIT	10.65
EV / FCF	7.59

Financial Position

The company has a current ratio of 17.75, with a Debt / Equity ratio of 0.01.

Current Ratio	17.75
Quick Ratio	17.71
Debt / Equity	0.01
Debt / EBITDA	0.07
Debt / FCF	0.05
Interest Coverage	2,294.41

Financial Efficiency

Return on equity (ROE) is 21.92% and return on invested capital (ROIC) is 15.71%.

Return on Equity (ROE)	21.92%
Return on Assets (ROA)	14.66%
Return on Capital (ROIC)	15.71%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.43
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -62.56% in the last 52 weeks. The beta is 1.31, so Handa Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	-62.56%
50-Day Moving Average	67.57
200-Day Moving Average	112.73
Relative Strength Index (RSI)	32.60
Average Volume (20 Days)	342,405

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Handa Pharmaceuticals had revenue of TWD 972.97 million and earned 452.32 million in profits. Earnings per share was 3.24.

Revenue	972.97M
Gross Profit	971.68M
Operating Income	525.42M
Pretax Income	587.13M
Net Income	452.32M
EBITDA	529.31M
EBIT	525.42M
Earnings Per Share (EPS)	3.24

Full Income Statement

Balance Sheet

The company has 2.53 billion in cash and 36.89 million in debt, giving a net cash position of 2.49 billion or 17.64 per share.

Cash & Cash Equivalents	2.53B
Total Debt	36.89M
Net Cash	2.49B
Net Cash Per Share	17.64
Equity (Book Value)	2.90B
Book Value Per Share	20.56
Working Capital	2.61B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 746.52 million and capital expenditures -1.68 million, giving a free cash flow of 744.84 million.

Operating Cash Flow	746.52M
Capital Expenditures	-1.68M
Free Cash Flow	744.84M
FCF Per Share	5.27

Full Cash Flow Statement

Margins

Gross margin is 99.87%, with operating and profit margins of 54.00% and 46.49%.

Gross Margin	99.87%
Operating Margin	54.00%
Pretax Margin	60.34%
Profit Margin	46.49%
EBITDA Margin	54.40%
EBIT Margin	54.00%
FCF Margin	76.55%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.71%.

Dividend Per Share	1.00
Dividend Yield	1.71%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	31.19%
Buyback Yield	-7.81%
Shareholder Yield	-6.10%
Earnings Yield	5.62%
FCF Yield	9.14%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Handa Pharmaceuticals has an Altman Z-Score of 54.71.

Altman Z-Score	54.71
Piotroski F-Score	n/a